1. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors [published correction appears in JAMA 1999;281:1174] JAMA. 1999;281:53744....

2. Bhasin S, Buckwalter JG. Testosterone supplementation in older men: a rational idea whose time has not yet come. J Androl. 2001;22:71831.

3. Liverman CT, Blazer DG, eds. Testosterone and aging: clinical research directions. Washington, D.C.: National Academies Press, 2004.

4. Griffin J, Wilson J. Disorders of the testes. In: Harrison TR, Braunwald E, eds. Harrison's Principles of internal medicine. 15th ed. New York: McGraw-Hill, 2001:214354.

5. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87:58998.

6. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. for the Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab. 2001;86:72431.

7. Rhoden EL, Morgentaler A. Risks of testosteronereplacement therapy and recommendations for monitoring. N Engl J Med. 2004;350:48292.

8. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients2002 update. Endocr Pract. 2002;8:44056.

9. Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab. 1981;53:5868.

10. Davidson JM, Camargo CA, Smith ER. Effects of androgen on sexual behavior in hypogonadal men. J Clin Endocrinol Metab. 1979;48:9558.

11. Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab. 1997;82:37936.

12. Skakkebaek NE, Bancroft J, Davidson DW, Warner P. Androgen replacement with oral testosterone undecenoate in hypogonadal men: a double blind controlled study. Clin Endocrinol (Oxf). 1981;14:4961.

13. Wang C, Swedloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000;85:283953.

14. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 1997;82:238690.

15. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2001;56:M26672.

16. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab. 1999;84:196672.

17. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab. 1999;84:264753.

18. Sih R, Morley JE, Kaiser FE, Perry HM III, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997;82:16617.

19. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000;85:26707.

20. Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, et al. Testosterone replacement therapy improves mood in hypogonadal mena clinical research center study. J Clin Endocrinol Metab. 1996;81:357883.

21. Dobs AS. Androgen therapy in AIDS wasting. Baillieres Clin Endocrinol Metab. 1998;12:37990.

22. Grinspoon S, Corcoran C, Stanley T, Baaj A, Basgoz N, Klibanski A. Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. J Clin Endocrinol Metab. 2000;85:605.

23. Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebocontrolled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry. 2000;57:1417.

24. Grinspoon S, Corcoran C, Parlman K, Costello M, Rosenthal D, Anderson E, et al. Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann Intern Med. 2000;133:34855.

25. Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab. 2001;86:355561.

26. Janowsky JS, Oviatt SK, Orwoll ES. Testosterone influences spatial cognition in older men. Behav Neurosci. 1994;108:32532.

27. Cherrier MM, Asthana S, Plymate S, Baker L, Matsumoto AM, Peskind E, et al. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology. 2001;57:808.

28. Meikle AW, Arver S, Dobs AS, Adolfsson J, Sanders SW, Middleton RG, et al. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology. 1997;49:1916.

29. Ferrando AA, Sheffield-Moore M, Yeckel CW, Gilkison C, Jiang J, Achacosa A, et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab. 2002;282:E6017.

30. Simon D, Charles MA, Lahlou N, Nahoul K, Oppert JM, Gouault-Heilmann M, et al. Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone: a 3-month randomized placebo-controlled trial. Diabetes Care. 2001;24:214951.

31. Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med. 2001;111:2619.

32. Watts NB, Notelovitz M, Timmons MC, Addison WA, Wiita B, Downey LJ. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause [published correction appears in Obstet Gynecol 1995;85(5 pt 1):668] Obstet Gynecol. 1995;85:52937.

33. Sherwin BB, Gelfand MM. Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. Am J Obstet Gynecol. 1985;151:15360.

34. Phillips E, Bauman C. Safety surveillance of esterified estrogens-methyl-testosterone (Estratest and Estratest HS) replacement therapy in the United States. Clin Ther. 1997;19:107084.

35. Gelfand MM, Wiita B. Androgen and estrogen-androgen hormone replacement therapy: a review of the safety literature, 1941 to 1996 Clin Ther. 1997;19:383404.

36. Barrett-Connor E, Young R, Notelovitz M, Sullivan J, Wiita B, Yang HM, et al. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. J Reprod Med. 1999;44:101220.

37. Singh AB, Hsia S, Alaupovic P, Sinha-Hikim I, Woodhouse L, Buchanan TA, et al. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab. 2002;87:13643.

38. Kaplan HS, Owett T. The female androgen deficiency syndrome. J Sex Marital Ther. 1993;19:324.

39. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:32133.

40. The Endocrine Society. Endocrine society calls for clinical guidelines on androgens for women. Accessed online October 19, 2005, at: http://www.endosociety.org/news/press/2004/androgenguidelines.cfm.

41. Wisniewski AB, Nguyen TT, Dobs AS. Evaluation of high-dose estrogen and high-dose estrogen plus methyltestosterone treatment on cognitive task performance in postmenopausal women. Horm Res. 2002;58:1505.

42. Bachmann GA, Leiblum SR, Sandler B, Ainsley W, Narcessian R, Shelden R, et al. Correlates of sexual desire in post-menopausal women. Maturitas. 1985;7:2116.

43. McCoy NL, Davidson JM. A longitudinal study of the effects of menopause on sexuality. Maturitas. 1985;7:20310.

44. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas. 1995;21:22736.

45. Lobo RA, Rosen RC, Yang HM, Block B, Van Der Hoop RG. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril. 2003;79:134152.

46. Sarrel P, Dobay B, Wiita B. Estrogen and estrogen-and rogen replacement in postmenopausal women dissatisfied with estrogen-only therapy. Sexual behavior and neuroendocrine responses. J Reprod Med. 1998;43:84756.

47. Burger H, Hailes J, Nelson J, Menelaus M. Effect of combined implants of oestradiol and testosterone on libido in postmenopausal women. Br Med J. 1987;294:9367.

48. Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med. 2000;343:6828.

49. Jassal SK, Barrett-Connor E, Edelstein SL. Low bioavailable testosterone levels predict future height loss in postmenopausal women. J Bone Miner Res. 1995;10:6504.

50. Riley A, Riley E. Controlled studies on women presenting with sexual drive disorder: I. Endocrine status. J Sex Marital Ther. 2000;26:26983.

51. Goldstat R, Briganti E, Tran J, Wolfe R, Davis SR. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause. 2003;10:3908.

52. Noakes TD. Tainted glorydoping and athletic performance. N Engl J Med. 2004;351:8479.

53. Schmidt PJ, Daly RC, Bloch M, Smith MJ, Danaceau MA, Clair LSSt., et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry. 2005;62:15462.

54. Lawrence ME, Kirby DF. Nutrition and sports supplements: fact or fiction. J Clin Gastroenterol. 2002;35:299306.

55. Lombardo JA. Supplements and athletes. South Med J. 2004;97:8779.

56. Green GA, Catlin DH, Starcevic B. Analysis of over-the-counter dietary supplements. Clin J Sport Med. 2001;11:2549.

57. Boehringer S. Comparison of testosterone products. Pharmacist's Letter. 2003;19:1983.

See more here:
Testosterone Treatments: Why, When, and How? - American ...

Low testosterone prevalence

Low testosterone (low T) affects 4 to 5 million men in the US.

Testosterone is an important hormone in the human body. But it starts to decrease each year after age 30. In some men this can be substantial. Between 19 and 39 percent of older men may have low levels of testosterone.

Older men with low T have increasingly sought testosterone replacement therapy (TRT) in recent years. TRT addresses symptoms such as low libido, poor muscle mass, and low energy.

Its not just older men that are affected by low T. Young men, even babies and children, can also have this problem.

Low levels of testosterone that are atypical of normal aging are due to other primary or secondary causes of hypogonadism. Hypogonadism in males happens when the testicles dont produce enough testosterone. Hypogonadism can start during fetal development, during puberty, or during adulthood.

If hypogonadism begins during fetal development, the primary result is impaired growth of external sex organs. Depending on when hypogonadism starts and the level of testosterone present during fetal development, a male child can develop:

Normal growth can be jeopardized if hypogonadism occurs during puberty. Problems occur with:

Later in life, insufficient testosterone can lead to other problems. Symptoms include:

Fatigue and mental fogginess are some commonly reported mental and emotional symptoms in men with low T.

9 Warning signs of low testosterone

The two basic types of hypogonadism are primary and secondary hypogonadism.

Underactive testes cause primary hypogonadism. Thats because they dont manufacture sufficient levels of testosterone for optimal growth and health. This underactivity can be caused by an inherited trait. It can also be acquired by accident or illness.

Inherited conditions include:

Types of testicle damage that can lead to primary hypogonadism include:

Secondary hypogonadism is caused by damage to the pituitary gland or hypothalamus. These parts of the brain control hormone production by the testes.

Inherited or disease conditions in this category include:

Acquired circumstances that can lead to secondary hypogonadism include:

You may be affected by primary, secondary, or a mixed hypogonadism. Mixed hypogonadism is more common with increased age. People undergoing glucocorticoid therapy can develop the condition. It also can affect people with sickle-cell disease, thalassemia, or alcoholism.

Learn more: 5 Natural testosterone boosters

If youre experiencing symptoms of low T, lifestyle changes may help to ease your symptoms.

A good first step is increasing activity levels and maintaining a healthy diet in order to reduce body fat. It can also be helpful to avoid glucocorticoid medications such as prednisone as well as opioid pain medications.

Diet right: 8 Testosterone boosting foods

If lifestyle changes dont work for you, you may need to begin testosterone replacement therapy (TRT) for treatment of low T. TRT can be very important for helping teenage males with hypogonadism experience normal masculine development. Sufficient testosterone levels help maintain health and well-being in adult males.

TRT has side effects, however, including:

A carefully formulated TRT treatment plan should avoid many of these undesirable side effects. Talk with your doctor to evaluate your options.

Options for increasing your testosterone

See original here:
Whats Causing My Low Testosterone?

A novel oral formulation of testosterone undecanoate (TU; trade name: Jatenzo) displayed a safety profile that is consistent with other approved testosterone products, according to a recent study.1

Investigators reporting their findings at the 2021 Sexual Medicine Society of North America Fall Scientific Meeting noted that no evidence of liver toxicity was observed with the treatment at 2 years.

For the study, the investigators conducted 2 open-label, multicenter, dose titration trials in men with hypogonadism (defined as serum testosterone of 300 ng/dL) aged 18 to 75 years. Trial 1 was a randomized, active-controlled, 2-arm, 12-month study, and Trial 2 was a long-term extension of those patients who completed Trial 1. Statistical analyses were only conducted with the subjects who completed Trial 1 and continued treatment in Trial 2, thus providing up to 2 full years of data, noted the authors.

Physical exam, adverse event reporting, and routine clinical laboratory measurements were used to evaluate safety.

A total of 86 patients participated in both trials. Testosterone concentration increased from 193.75 9.44 ng/dL (mean SEM) at baseline to 475.5 49.7 ng/dL after 24 months of therapy with oral TU. In addition, 84% of men achieved testosterone in the eugonadal range (300 ng/dL to 1000 ng/dL) after 90 days of therapy.

The investigators reported that mean testosterone concentrations remained in the eugonadal range throughout Trial 2. In addition, there were no clinically significant changes in liver function tests throughout the 2 trials. At day 270, 1 patient had an ALT level of 227 U/L, which was more than 4 times the ULN. The patients ALT was measured again at day 290 after continued TU use, and the level had dropped to 87 U/L, or less than 2 times the ULN.

A modest initial increase in prostate-related growth end points (ie, prostate-specific antigen and prostate volume) was reported that stabilized over time. There were no significant changes in International Prostate Symptom Score total score observed.

There were significant, yet modest, increases in mean HCT (44.3 0.3 to 46.6 0.5%, P < .001) and cuff systolic BP (127.1 1.2 to 131.8 1.67 mmHg vs BL, P = .006), the authors wrote. Cardiovascular end points such as HDL-C, hematocrit, and blood pressure changed initially and then stabilized throughout the trials.

The long-term efficacy and safety profile of oral TU may provide a treatment option that avoids issues associated with other [testosterone replacement therapies], such as injection site pain or transference to partners and children, the authors concluded.

Reference

1. Swerdloff R, Honig S, Wang C, et al. Two-year administration data of an oral testosterone undecanoate (TU) formulation in hypogonadal men. Real-world experience with first FDA-approved oral testosterone undecanoate formulation. Paper presented at 2021 Sexual Medicine Society of North America Fall Scientific Meeting; October 21-24, 2021; Scottsdale, Arizona. Abstract 003.

Continued here:
Oral formulation of testosterone displays safety at 2 years - Urology Times

Global Testosterone Replacement Therapy Sales Market Report provides a detailed Industry overview along with the analysis of Cost Structure, Supply Chain, Development Management Techniques, Retailers Analysis, Financial Support, business Strategies, Marketing Channels. Global Testosterone Replacement Therapy Sales Market research report provides a point-by-point In-Depth analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, the impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Request For Sample Copy of This Premium Research Testosterone Replacement Therapy Sales Market: https://www.stratagemmarketinsights.com/sample/8711

PDF report & online dashboard will help you understand: Competitive Landscape Historical data & forecasts Company revenue shares Regional assessment Latest trends & dynamics

The Testosterone Replacement Therapy Sales Market study report will provide a valuable insight with an emphasis on the global market including some of the major players such as AbbVie, Endo International, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals

Key Market Segmentation:

Stratagem Market Insights provides an analysis of the key trends in each sub-segment of the global Testosterone Replacement Therapy Sales market, along with forecasts at the global, regional, and country-level analysis from 2021-2028. Our report has categorized the market based on type, offering, technology, system, and end-use industry.

Scope of the Testosterone Replacement Therapy Sales Market Report:

With the slowdown in world economic growth, the Testosterone Replacement Therapy Sales industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past five years, Testosterone Replacement Therapy Sales market size to maintain theaverage annual growth ratein 2014 to 2020, analysts believe that in the next few years, Testosterone Replacement Therapy Sales market size is anticipated to rise at a considerable rate during the forecast period, by 2028. This Report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution, etc., these data help the consumer know about the competitors better.

Dont miss out on business opportunities in Testosterone Replacement Therapy Sales Market. Speak to our analyst and gain crucial industry insights that will help your business grow @ https://www.stratagemmarketinsights.com/speakanalyst/8711

This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume, and value, as well as price data. Besides, the report also covers segment data, including type segment, industry segment, channel segment, etc. cover different segment market sizes, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.

This Report lets you identify the opportunities in Testosterone Replacement Therapy Sales Market by means of a region:

North America (the United States, Canada, and Mexico) Europe (Germany, UK, France, Italy, Russia and Turkey, etc.) Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia (Indonesia, Thailand, Philippines, Malaysia, and Vietnam)) South America (Brazil etc.) The Middle East and Africa (North Africa and GCC Countries)

This Testosterone Replacement Therapy Sales reports market status and outlook of global and major regions, from angles of players, countries, product types, and end industries; this report analyzes the top players in the global industry and splits by product type and applications/end industries. This report also includes the impact of COVID-19 on the Testosterone Replacement Therapy Sales industry. Global Testosterone Replacement Therapy Sales Industry 2021 Market Research Report is spread across 120+ pages and provides exclusive vital statistics, data, information, market trends, and competitive landscape details in this niche sector.

Testosterone Replacement Therapy Sales Market insights will improve the revenue impact of businesses in various industries :

Providing a framework tailored toward understanding the attractiveness quotient of various products/solutions/technologies in the Testosterone Replacement Therapy Sales Market Guiding stakeholders to identify key problem areas pertaining to their consolidation strategies in the global Testosterone Replacement Therapy Sales market and offers solutions Assessing the impact of changing regulatory dynamics in the regions in which companies are keen on expanding their footprints Provides an understanding of disruptive technology trends to help businesses make their transitions smoothly Helping leading companies make strategy recalibrations ahead of their competitors and peers Offers insights into promising growth for top players aiming to retain their leadership position in the market & supply-side analysis of the Testosterone Replacement Therapy Sales market.

Buy This Research Study Report For Quick Access- https://www.stratagemmarketinsights.com/cart/8711

In conclusion, the Testosterone Replacement Therapy Sales market report presents the descriptive analysis of the parent market supported elite players, present, past, and artistic movement information which is in a position to function as a profitable guide for all the Testosterone Replacement Therapy Sales industry business competitors. Our expert research analysts team has been trained to supply in-depth marketing research reports from every individual sector which can be helpful to know the industry data within the most precise way.

Fr th Testosterone Replacement Therapy Sales rkt rrh tud, th fllwng r hv bn ndrd t tmt th mrkt z:

tr Yr: 2015 t 2020tmtd Yr: 2021Frt Yr: 2022 t 2028

Contact Us:

Mr. ShahStratagem Market InsightsTel: US +1 415 871 0703 / JAPAN +81-50-5539-1737Email: sales@stratagemmarketinsights.com

AJ

See more here:
Testosterone Replacement Therapy Sales Market Outlooks 2021 Industry Analysis, Growth Strategies, Latest Trends Forecast Period Of 2021-2028 IMIESA -...

LONDON Men with high testosterone are more likely to have multiple partners in the bedroom at the same time a new study reveals. Scientists say, in women, the hormone leads to more masturbation or same-sex flings.

Testosterone replacement therapy is becoming increasingly popular to boost mens energy, mood, and sex drive. Study authors found that men with higher testosterone levels were more likely to have more than one lover over the same period in the last five years. These men were also more likely to have had sex recently.

In women, the study finds testosterone was significantly higher among those who reported having a same-sex relationship at some point. Women with higher testosterone levels also reported masturbating more recently and frequently.

The findings come from a review of almost 4,000 adults. Study authors say their results help to address the deficit in research into the role of androgens in womens sexuality. Scientists commonly regard testosterone as the biological driver of sexual desire in men, although evidence is inconclusive. Its role in female desire is even less understood.

Theres a sparsity of population level data on the differences between men and women in the relationship between testosterone and sexual function, attitudes and behavior, says study lead author Wendy Macdowall of the London School of Hygiene and Tropical Medicine in a media release. Questions have been raised about the nature of sexual desire in women and how little we understand about what it is that is desired.

Our data tend to confirm that differences between men and women need to be understood by examining them in the context of social as well as hormonal influences on sexual function and behavior. Testosterones marked link with masturbation among women, in the absence of an observed link with aspects of heterosexual partnered sex, may be seen as consistent with the notion of a stronger moderating effect of social factors on hormonal influences on womens behavior, Macdowall explains.

The study analyzed data from the third British National Survey of Sexual Attitudes and Lifestyles. Past research on hormones and female sexuality has tended to focus solely on aspects of reproduction, such as menstruation. In men, the focus has been on their role in the ability to perform sexually, such as to achieve an erection.

Researchers scanned saliva samples from 3,722 participants between 18 and 74 years-old 1,599 men and 2,123 women using a state-of-the-art technique. Those who had at least one sexual partner in the year before the interview answered questions about problems with sexual function, such as lacking interest in having sex and having trouble getting or keeping an erection.

The team measured a range of behaviors, including different practices in the previous four weeks, frequency of masturbation, and the number and type of partners over the past five years and their lifetime. Participants also gave their views about different types of sexual relationships, such as one-night stands.

Overall, the report finds a stronger link for women than for men between higher testosterone levels and solitary sexual activity. The researchers add this could have a connection to the different meanings and motivations women attach to solitary and partnered sex.

The male sex hormone comes mainly from the testicles, but also from the adrenal glands, which are near the kidneys. It causes the voice to deepen, body hair to grow, and the genitals to become larger during puberty. As well as affecting sex drive and sperm production, it also plays a role in developing strong bones and muscles, and how the body distributes fat.

Women also create small amounts of testosterone in the ovaries and adrenal glands. It affects their fertility, bones, and muscles.

Low testosterone in men can cause erection problems, low sex drive, infertility, weakened muscles and bones, body fat gain, and hair loss. Too much testosterone, however, can trigger puberty in boys under the age of nine, which has a link to aggression and can increase the risk of prostate problems and cancer.

A males testosterone levels tend to be highest at around 20 years-old and declines naturally with age. Higher levels in men also show a link to risk-taking behavior, as well as increased attraction to the opposite sex.

Men have, on average, six times as much testosterone as women. At the same time, previous studies point to men having considerably higher rates of unfaithful behavior. They tend to seek more frequent sexual encounters due to the evolutionary reproductive benefits of having multiple partners. Men with high levels of testosterone also tend to have the perception of being more attractive to women.

The findings appear in The Journal of Sex Research.

South West News Service writer Mark Waghorn contributed to this report.

Link:
Men with high testosterone are more likely to cheat, study suggests - Study Finds

Aspiration Control Systems Market Overview 2021 2026

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

The risingtechnology in Aspiration Control Systems Marketis also depicted in thisresearchreport. Factors that are boosting the growth of the market, and giving a positive push to thrive in the global market is explained in detail. The study considers the present scenario of the data center power market and its market dynamics for the period 2021-2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.

Get a Sample PDF copy of the report @ https://www.reportsinsights.com/sample/557830

Key Competitors of the Global Aspiration Control Systems Market are:Testosterone Replacement Therapy, Estrogen Therapy, Progesterone Therapy,

Historical data available in the report elaborates on the development of the Aspiration Control Systems on national, regional and international levels. Aspiration Control Systems Market Research Report presents a detailed analysis based on the thorough research of the overall market, particularly on questions that border on the market size, growth scenario, potential opportunities, operation landscape, trend analysis, and competitive analysis.

Major Product Types covered are:

Testosterone Replacement TherapyEstrogen TherapyProgesterone TherapyMarket size by End UserHospitals including hospital pharmaciesClinicsRetail pharmacies

market while maintaining their competitive edge over their competitors. The report offers detailed and crucial information to understand the overall market scenario.

This study report on global Aspiration Control Systems market throws light on the crucial trends and dynamics impacting the development of the market, including the restraints, drivers, and opportunities.

To get this report at a profitable rate.: https://www.reportsinsights.com/discount/557830

The fundamental purpose of Aspiration Control Systems Market report is to provide a correct and strategic analysis of the Aspiration Control Systems industry. The report scrutinizes each segment and sub-segments presents before you a 360-degree view of the said market.

Market Scenario:

The report further highlights the development trends in the global Aspiration Control Systems market. Factors that are driving the market growth and fueling its segments are also analyzed in the report. The report also highlights on its applications, types, deployments, components, developments of this market.

Highlights following key factors:

:-Business descriptionA detailed description of the companys operations and business divisions.:-Corporate strategyAnalysts summarization of the companys business strategy.:-SWOT AnalysisA detailed analysis of the companys strengths, weakness, opportunities and threats.:-Company historyProgression of key events associated with the company.:-Major products and servicesA list of major products, services and brands of the company.:-Key competitorsA list of key competitors to the company.:-Important locations and subsidiariesA list and contact details of key locations and subsidiaries of the company.:-Detailed financial ratios for the past five yearsThe latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Our report offers:

Market share assessments for the regional and country level segments. Market share analysis of the top industry players. Strategic recommendations for the new entrants. Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets. Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations). Strategic recommendations in key business segments based on the market estimations. Competitive landscaping mapping the key common trends. Company profiling with detailed strategies, financials, and recent developments. Supply chain trends mapping the latest technological advancements.

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://www.reportsinsights.com/industry-forecast/Aspiration-Control-Systems-Market-557830

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

Email:[emailprotected]

Sales:[emailprotected]

Read more here:
Aspiration Control Systems Market Provide In-Depth and Visionary Insights Research, Recent Trends and Growth Forecast by 2026 Puck77 - Puck77

Its been more than three years since trailblazing transgender hockey player Harrison Browne laced up his skates and played in a competitive game. And now hes itching to get back on the ice, fears be damned.

Earlier this week, Browne, who is the first publicly out trans pro hockey player in America and won two championships in the PHF, posted a message on Twitter about his ever-changing relationship with the sport he loves. After retiring, Browne started physically transitioning, a process that is now complete.

While Brown is in a great personal place hes now a working actor and played a transgender character in an episode of the Hulu series, The Last Man, his physical changes have paused his ambitions to play again.

For starters, Browne, who was a PHF All-Star in 2017, doesnt know which level would be appropriate for him. He knows hes not at the NHL level, but at the same time, doesn't want to play against inferior competition.

Then theres the locker room. Its common practice for male hockey players to shower in one big stall after games. The prospect of doing that makes Browne uncomfortable.

There is something about hockey and the dressing room that does hold me back, and thats the showering situation, he said. Theres a lot of nudity in hockey. Its hard to explain.

But Browne is trying. Hes been public about every step of his transition, posting selfies and even bragging about cutting himself while shaving (a right of passage for any man). His inner-dialogue about whether he wants to come back and play the sport he loves isnt any different.

Some acting gigs, including a recent commercial for Scotia Bank in Canada that pushes for inclusion in hockey, have rekindled his passion for the game.

It made me realize how much I really missed being on the ice, and the last couple of months Ive been jonesing to get back on the ice, he said.

The PHF, Brownes old league, announced last week a comprehensive transgender and nonbinary inclusion policy. It says transgender women are eligible to play if theyve been living in their transgender identity for a minimum of two years, and trans men can play as well, provided they obtain a therapeutic use exemption if they are taking testosterone.

People wondered why I was immediately eliminated from playing in that league just because I had a shot of testosterone. I didnt really have an answer for that, Browne said. Its really cool to see there is some inclusion of trans men within that league that are on hormone-replacement therapy. Its really great to have those conversations.

As for Browne, hes going to continue to have conversations with those closest to him about a potential return to the ice. The first step will come Nov. 11, when he plays in the Eric Lindros Celebrity Hockey Classic. The game is raising money for Easter Seals, an organization that helps kids with physical disabilities attend summer camp and participate in other recreational activities.

One thing is for sure: Browne doesnt want to let fear determine his path.

I dont want to not do something out of fear, he said. Why should I feel like Im not included in this sport that Ive given my life to, that Ive made a lot of accomplishments in. Why should I not do something I want to do?

Follow Harrison Browne on Twitter and Instagram.

Originally posted here:
Harrison Browne, trans pro hockey player, wants to return to the ice - Outsports